The Nutrigenomics and Metabolic Syndrome research group is a consolidated group of IMIBIC, bringing together both basic and clinical researchers in various scientific disciplines, such as medicine, biology, biochemistry, as well as dieticians and nursing. Our research is mainly based on the effect of dietary components on cardiovascular risk through a double approach: the biological actions of the diet on mechanisms and factors related to the development of atherosclerosis (oxidative stress, inflammation, homeostasis or cellular signaling) and Nutrigenetics, through which we investigate how common genetic variants modulate the influence of the diet on different markers such as postprandial metabolism, endothelial function, overweight or glucose metabolism. We are also interested in the use of these strategies in others pathologies such as hypercholesterolemia, thromboembolic disease, as well as in ageing process. These approaches will allow us to modulate the pathological pathways that underlie the development of various chronic diseases (type 2 diabetes mellitus, metabolic syndrome and cardiovascular diseases).
Over the last few years, our group has been developing predictive models for assessing the risk of disease. Specifically, we are developing innovative models to evaluate biological senescence, coronary heart disease treatment choice and miRNAs plasma levels-based model for type 2 diabetes mellitus development. Moreover, due to the complex nature of gene-environment interactions, another important aim of our research is to establish an appropriate dietary therapy in according to the disease, for personalized nutrition.
Our research group is highly motivated toward internationalization. In fact, we are currently taking part in two international consortiums. POWER2DM, whose objective is to develop individual self-control of diabetes; and FAME, for the identification of new disease biomarkers.